Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical trial NCT01896999 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT01896999
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-07
- Primary completion
- 2026-12-31
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.